氦氖激光血管内照射配合吗啡控制癌痛的对照观察

目的探讨氦氖激光血液照射辅助治疗控制癌痛的疗效。方法对52例中晚期癌症重度痛患者在使用口服吗啡治疗基础上加用低能量氦氖激光血液照射治疗1周后,对疼痛缓解程度及平均缓解时间进行对照观察。结果加用激光照射组的镇痛疗效优于单用吗啡组,P<0.05,有效率分别为92%和84%,P>0.05,显效率分别为67%和46%,u=2.07,P<0.05,均数缓解时间分别为(8±3)h和(8±4)h,t=0.78,P>0.05,差异无显著性意义。结论氦氖激光血液照射治疗有一定协同镇痛作用。     

不同输血方式对肺鳞癌患者围术期TNF—α和IL—lO的影响

[目的]探讨同种输血和自体输血对肺鳞癌患者围术期肿瘤坏死因子-α(TNF-α)和白细胞介素—10(IL—10)的影响和相互关系。[方法]2001年1月至2003年1月对31例肺鳞癌患者行肺癌根治术，将其分为两组，同种输血组(A组)17例，自体输血组14例(B组)。测定两组围术期血清中TNF-α和IL—10的浓度。[结果]A组输血后d1与输血前相比血清中TNF-α、IL-10浓度增高，以IL—10变化尤为明显，输血后d5TNF-α降低并接近输血前的水平，明显低于B组，IL—10仍明显高于输血前的水平。B组中不同时问IL—10无显著变化，TNF-α于ds明显高于输血前。[结论]肺鳞癌患者围术期同种输血后血清中TNF-α降低与IL—10升高有关，IL—10升高可能是同种输血后免疫抑制的重要原因。自体输血可减轻或去除这一作用。     

Predictors of long-term survival in patients with gallbladder cancer

The aim of this study was to examine the predictors of long-term survival (>24 months) in patients with gall bladder cancer. A retrospective review of 117 cases of gall bladder cancer resected between 1989 and 2000. The resections included 80 simple cholecystectomies and 37 extended procedures. Patients with survival >24 months (n=44) were compared with those having survival <24 months (n=73) for 17 prognostic factors. Overall median survival was 16 months with a 5-year survival of 27%. T status (P=.000) and adjuvant chemoradiotherapy (P=.001) were independent predictors of long-term survival. Survival advantage was seen in T3N+ve disease (P=.007) with extended procedures. Complete (R0) resection was attained in 30 patients with a 5-year survival advantage of 30% as compared with incomplete (R1) resection (P=.0002). Adjuvant chemoradiotherapy improved survival in simple cholecystectomy group (P=.0008) but no advantage was seen after extended procedures. Stage III (P=.001) and node-positive disease (P=.0005) had significant benefit with adjuvant therapy. Poor differentiation and vascular invasion were associated with poor long-term survival. R0 resection was associated with prolonged survival. Extended procedures improved survival in patients with T3N+ve disease. Addition of chemoradiotherapy made significant improvement in long-term survival in stage III and node-positive lesions and in patients undergoing simple cholecystectomy. R0 resection predicted long-term survival in gall bladder cancer. T3 N+ve disease had better survival after extended procedures. Adjuvant chemoradiotherapy improved survival in stage III and node-positive disease. Poor differentiation and vascular invasion were adverse predictors of survival.     

抑癌基因KLF-6和APC在结直肠癌组织中的表达及临床意义

目的 研究抑癌基因KLF-6和APC在结直肠癌中的表达规律及其临床意义。方法 应用RT-PCR和免疫组织化学法对32例结直肠癌组织和正常黏膜组织中KLF-6和APC基因mRNA及蛋白的表达进行检测和分析。结果 KLF-6与APC的mRNA阳性表达率在结直肠癌组织中分别为37、5％和34，3％，明显低于正常结直肠黏膜组织的96．9％和93．8％（P〈0．05）。KLF-6与APC的免疫组化染色阳性表达率在结直肠癌组织中分别为28．1％和25．0％，明显低于正常结直肠黏膜组织的81．3％和84．4％（P〈0．05）。KLF-6与APC在结直肠癌中的表达存在相关性（P〈0．05），并与肿瘤组织的分化程度、浸润深度、淋巴结转移及临床分期均有明显相关性（P〈0．05）。结论 抑癌基因KLF-6和APC的低表达可能与结直肠癌的发生、发展、转移及预后有关，且两者存在相关性。     

11C-乙酸盐PET显像在肾脏肿瘤诊断中的作用

目的探讨^11C-乙酸盐PET显像在肾脏肿瘤诊断中的作用及其与^18F-脱氧葡萄糖（FDG）肾肿瘤显像的关系。方法29例疑肾肿瘤患者行^11C-乙酸盐PET早期及延迟显像，其中22例1周内行^18F—FDG PET显像。所有患者均有手术病理检查或CT、随访结果。患者静脉注射^11C-乙酸盐后即刻采集肾脏部位早期图像，以反映肾皮质血流灌注；10min后采集延迟图像，以反映^11C-乙酸盐在肾皮质内的代谢。观察^11C-乙酸盐在人体内的分布，并比较^11C-乙酸盐与^18F—FDG肾肿瘤显像的阳性率及其与病理类型、分级的关系。结果^11C-乙酸盐在人体内以胰腺摄取最高，并可能经胰液分泌人肠道。肾皮质对^11C-乙酸盐摄取随时间而变化，延迟相大部分原发肾皮质肿瘤（13例中分级Ⅰ～Ⅱ为12例）对^11C-乙酸盐摄取高于正常肾皮质，阳性率为76．9％（10／13例）；而^18F—FDG显像仅为30．8％（4／13例）。6例肾盂输尿管移行细胞癌^11C-乙酸盐显像阳性仅2例；其中5例行^18F—FDG显像，均阳性。1例肾血管平滑肌脂肪瘤^11C-乙酸盐早期及延迟显像均清晰显示，2例输尿管炎症对^11C-乙酸盐无摄取。结论^11C-乙酸盐PET显像对恶性程度较低的肾皮质肿瘤显像阳性率较高，可弥补^18F—FDG显像的不足。     

PTEN及Bcl-2蛋白在膀胱移行细胞癌中的表达及其意义

目的：探讨PTEN及Bcl-2蛋白在膀胱移行细胞癌的表达规律及其临床意义。方法：应用免疫组织化学链亲和素-生物素-霉复合物（SP）方法检测43例膀胱移行细胞癌和7例正常黏膜组织中PTEN及Bcl-2蛋白的表达．分析二者的表达与膀胱癌病理参数的关系。结果：（1）G1、G2、G3肿瘤PTEN表达阳性率分别为85．7％、80．4％、73．3％，浸润性肿瘤和表浅性肿瘤表达阳性率分别为70．4％和93．8％，说明PTEN表达阳性率与肿瘤病理分级、临床分期有关。（2）G。、G2、G3肿瘤Bcl-2表达阳性率分别为14．2％、57．14％、66．67％，浸润性肿瘤和表浅性肿瘤表达阳性率分别为59．3％和43．8％，说明Bcl-2表达阳性率与肿瘤病理分级、临床分期有关。（3）随着肿瘤恶性程度的增高和临床分期进展，PTEN蛋白阳性率呈下降，Bcl-2表达呈增高趋势，二者表达呈负相关关系。结论：PTEN的抑癌作用可能与Bcl-2有关．二者的异常表达在膀胱移行细胞癌的发生、发展过程中起重要作用。二者同时检测有助于判断预后。     

Predictors of gastric emptying in Parkinson''s disease

Predictors of gastric emptying (GE) in patients with idiopathic Parkinson's disease (PD) of a solid and liquid meal are not well defined. For measurement of GE 80 patients with PD were randomly assigned to receive either a solid meal (250 kcal) containing 13C-octanoate (n = 40) or a liquid meal (315 kcal) with 13C-acetate (n = 40). All patient groups were off medication affecting motility and were matched for age, gender, body mass index, disease duration and severity, using Unified Parkinson's Disease Rating Scale (UPDRS). Gastric emptying was compared with a healthy control group (n = 40). Multiple regression analysis was used to determine predictors of gastric emptying. Exactly 88% and 38% of PD patients had delayed GE of solids and liquids respectively. Solid and liquid emptying was similar in women and men. There were no differences in GE in PD patients < 65 years of age when compared with patients > or = 65 years. Multiple regression analysis showed that motor handicaps such as rigour and action tremor are independent predictors of solid GE (r = 0.68, P < 0.001). The severity of motor impairment, but not any other neurological symptom, as assessed by UPDRS is associated with gastroparesis in PD and solid emptying is more likely to be delayed.     

肾移植术后并发尿路上皮肿瘤的临床分析

目的 分析肾移植患者并发尿路上皮肿瘤的特点，探讨其诊治方法。方法 自1998～2003年肾移植患者1293例，术后发生尿路上皮恶性肿瘤21例（1．6％）。男4例，女17例。17例原发病为慢性问质性肾炎。发生尿路上皮肿瘤距肾移植6～62个月，平均26个月。其中膀胱癌6例，单侧肾盂或输尿管癌6例，单侧肾盂或输尿管、膀胱癌8例，双侧肾盂输尿管癌1例。10例上尿路肿瘤发生部位与移植肾同侧，4例发生于移植肾对侧。临床症状以无痛性肉服血尿和反复泌尿系感染为主。19例行手术治疗，术后所有患者免疫抑制剂用量减少1／3并辅以局部灌注化疗。结果 2例行姑息性治疗的晚期肿瘤患者分别于发现肿瘤5、8个月死亡。余19例现已随访2～5年。13例肿瘤复发，复发部位为膀胱或对侧原。肾、输尿管。所有患者在免疫抑制剂减量期间均未出现急性排斥。2例因切除移植肾恢复透析，17例肾功能正常。结论 慢性间质性。肾炎导致。肾功能衰竭的。肾移植患者和女性肾移植患者易发生移植后尿路上皮肿瘤；移植肾同侧上尿路较对侧好发肿瘤；对移植肾对侧为首发的上尿路发生肿瘤者可预防性行双侧上尿路根治性切除。